SCHEMBL5887428

SCHEMBL5887428

COC(=O)c1ccc(CNC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(N5CCN(C(C)=O)CC5)nc43)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
HTT P42858 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CTNNB1 P35222 1/20 0.39
TCF7L2 Q9NQB0 1/20 0.39
MAPK8 P45983 2/20 0.38
MAPK9 P45984 2/20 0.38
MAPK10 P53779 2/20 0.38
ALDH1A1 P00352 4/20 0.38
ENPP2 Q13822 5/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
ALOX15 P16050 2/20 0.37
ALOX12 P18054 2/20 0.37
HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886804 0.94 SMN1; SMN2 (0.42) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5887316 0.92 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5887099 0.92 SMN1; SMN2 (0.42) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5886773 0.92 KMT2A (0.46) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5887394 0.91 ACHE (0.44) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5886700 0.91 MGLL (0.42) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5886964 0.90 MAPK8 (0.45) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5886747 0.90 SMN1; SMN2 (0.42) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5886791 0.90 ENPP2 (0.48) SMN1; SMN2KMT2AMEN1CYP2C19LMNA
SCHEMBL5887019 0.89 ALDH1A1 (0.41) SMN1; SMN2KMT2AMEN1CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP SMN1; SMN2 2219/4885KMT2A 1530/4885MEN1 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.